TY - JOUR
T1 - Bioreactor technologies to support liver function in vitro
AU - Ebrahimkhani, Mohammad R.
AU - Neiman, Jaclyn A.Shepard
AU - Raredon, Micha Sam B.
AU - Hughes, David J.
AU - Griffith, Linda G.
N1 - Funding Information:
Funding from the NIH ( R01 EB 010246 , P50-GM068762-08 , R01-ES015241 , and P30-ES002109 ), 5UH2TR000496-02, the National Science Foundation ( CBET-0939511 NSF STC Emergent Behavior of Integrated Cellular Systems), and the Defense Advanced Research Projects Agency Microphysiological Systems Program: W911NF-12-2-0039.
PY - 2014
Y1 - 2014
N2 - Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.
AB - Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models.
KW - Bioreactor
KW - Drug development
KW - Drug toxicity
KW - Hepatocytes
KW - Liver non-parenchymal cells
KW - Microfluidic
KW - Organ on chip
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=84899986727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899986727&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2014.02.011
DO - 10.1016/j.addr.2014.02.011
M3 - Review article
C2 - 24607703
AN - SCOPUS:84899986727
SN - 0169-409X
VL - 69-70
SP - 132
EP - 157
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -